Suppr超能文献

由假单胞菌引起的与腹膜透析相关的腹膜炎:后千年病例系列的启示。

Peritoneal dialysis-related peritonitis caused by Pseudomonas species: Insight from a post-millennial case series.

机构信息

Nephrology Department, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.

出版信息

PLoS One. 2018 May 10;13(5):e0196499. doi: 10.1371/journal.pone.0196499. eCollection 2018.

Abstract

BACKGROUND

Pseudomonas peritonitis is a serious complication of peritoneal dialysis (PD). However, the clinical course of Pseudomonas peritonitis following the adoption of international guidelines remains unclear.

METHODS

We reviewed the clinical course and treatment response of 153 consecutive episodes of PD peritonitis caused by Pseudomonas species from 2001 to 2015.

RESULTS

Pseudomonas peritonitis accounted for 8.3% of all peritonitis episodes. The bacteria isolated were resistant to ceftazidime in 32 cases (20.9%), and to gentamycin in 18 cases (11.8%). In 20 episodes (13.1%), there was a concomitant exit site infection (ESI); in another 24 episodes (15.7%), there was a history of Pseudomonas ESI in the past. The overall primary response rate was 53.6%, and complete cure rate 42.4%. There was no significant difference in the complete cure rate between patients who treated with regimens of 3 and 2 antibiotics. Amongst 76 episodes (46.4%) that failed to respond to antibiotics by day 4, 37 had immediate catheter removal; the other 24 received salvage antibiotics, but only 6 achieved complete cure.

CONCLUSIONS

Antibiotic resistance is common amongst Pseudomonas species causing peritonitis. Adoption of the treatment guideline leads to a reasonable complete cure rate of Pseudomonas peritonitis. Treatment with three antibiotics is not superior than the conventional two antibiotics regimen. When there is no clinical response after 4 days of antibiotic treatment, early catheter removal should be preferred over an attempt of salvage antibiotic therapy.

摘要

背景

铜绿假单胞菌性腹膜炎是腹膜透析(PD)的严重并发症。然而,采用国际指南后铜绿假单胞菌性腹膜炎的临床病程仍不清楚。

方法

我们回顾了 2001 年至 2015 年期间 153 例由铜绿假单胞菌引起的 PD 腹膜炎连续发作的临床过程和治疗反应。

结果

铜绿假单胞菌性腹膜炎占所有腹膜炎发作的 8.3%。分离出的细菌中有 32 例(20.9%)对头孢他啶耐药,18 例(11.8%)对庆大霉素耐药。20 例(13.1%)伴有出口部位感染(ESI);另有 24 例(15.7%)既往有铜绿假单胞菌 ESI 病史。总的初始反应率为 53.6%,完全治愈率为 42.4%。用 3 种和 2 种抗生素治疗方案的完全治愈率无显著差异。在第 4 天抗生素治疗失败的 76 例(46.4%)中,37 例立即拔除导管;其余 24 例接受挽救性抗生素治疗,但只有 6 例完全治愈。

结论

引起腹膜炎的铜绿假单胞菌耐药很常见。采用治疗指南可使铜绿假单胞菌性腹膜炎获得合理的完全治愈率。使用 3 种抗生素并不优于常规的 2 种抗生素方案。如果抗生素治疗 4 天后无临床反应,应优先考虑早期拔管,而不是尝试挽救性抗生素治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3904/5944923/272624b97301/pone.0196499.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验